PR Newswire Clinical TrialsOriginal article
New Biomarker Data Presented in a Late Breaking Oral Presentation at EADV Congress 2026 Showing Early Molecular Responses to Rezpegaldesleukin Across Multiple Immune Pathways Dysregulated in Patients with Atopic Dermatitis
ConferencepositiveRezpegaldesleukinPositive
AI Analysis
Summary
Nektar Therapeutics presented late-breaking biomarker data at EADV Congress 2026 showing rezpegaldesleukin-associated early molecular responses in atopic dermatitis patients as early as Week 2, significantly correlated with subsequent clinical response across multiple dysregulated immune pathways.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
Early molecular responses detected as early as Week 2 across multiple immune pathways dysregulated in atopic dermatitis patients; improvements significantly correlated with subsequent clinical response
Importance:6/10
Sentiment:
0.65
atopic dermatitisbiomarker dataimmunologyEADV Congress 2026late breaking oral presentation
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on September 30, 2026 2:30 PM